Absci ramps R&D for AI drug creation; partner revenue falls and losses widen

Snapshot - Absci Corporation (NASDAQ: ABSI)
Quick take: Absci is ramping R&D and advancing its AI-driven drug-creation platform (ABS‑101 entered Phase 1 in May 2025) while revenue from partner programs has fallen and losses/cash burn remain material.

Key points & statistics (facts from the 10‑Q)
* Partner program revenue - Q2 2025: $0.593M (Q2 2024: $1.270M; down 53% YoY).
* Six months partner revenue - H1 2025: $1.772M (H1 2024: $2.168M; down 18%).
* Research & development expense - Q2 2025: $20.458M (Q2 2024: $15.261M; +34%); H1 2025: $36.822M (H1 2024: $27.497M; +34%).
* Total operating expenses - Q2 2025: $31.986M (Q2 2024: $27.991M; +14%); H1 2025: $60.894M (H1 2024: $52.387M; +16%).
* Operating loss - Q2 2025: $(31.393)M; H1 2025: $(59.122)M.
* Net loss - Q2 2025: $(30.569)M (EPS $(0.24)); Q2 2024: $(24.750)M (EPS $(0.22)). H1 2025 net loss: $(56.915)M (EPS $(0.45)).
* Cash, cash equivalents and short‑term investments - June 30, 2025: cash $38.024M + short‑term investments $79.434M = ~$117.5M total. Restricted cash $17.263M (includes $15.0M contingent in escrow).
* Operating cash burn - Net cash used in operating activities H1 2025: $(38.712)M (H1 2024: $(34.706)M).
* Balance sheet - Total assets $209.892M; total liabilities $36.519M; stockholders' equity $173.373M; accumulated deficit $566.516M.
* Share count - Weighted avg shares (basic & diluted) Q2 2025: 127,592,948 (up from 112,934,086).
* Financing activity H1 2025 - Proceeds from issuance of common stock (PIPE with AMD + ATM) netted $41.7M. Subsequent to quarter: additional share sales (ATM + underwritten offering) generated approx. $60.6M net proceeds (July 2025 events).

What's happening inside the company - operational highlights
* Platform investment: management is increasing R&D spend to advance internally developed programs and platform capabilities (R&D +34% YoY for the six‑month period).
* Clinical progress: ABS‑101 (IBD) Phase 1 dosing started May 2025; company expects interim readout H2 2025. ABS‑201 (androgenetic alopecia) targeted IND/H1 2026 filing (per MD&A).
* Strategic partnerships / capital: strategic collaboration and $20.0M PIPE with AMD (Jan 2025) to optimize compute for AI drug creation; active ATM program and July 28, 2025 underwriting raised ~ $46.7M net. These capital actions materially supplement liquidity.
* Revenue mix & concentration: partner revenue is project/milestone driven and highly concentrated - two partners represented ~99% of Q2 2025 revenue and three partners 100% for H1 2025.

Income statement - positives
* Management is investing in product and platform validation: R&D increases are funding advancement of internal candidates (ABS‑101, ABS‑201) - essential for longer‑term value creation.
* SG&A roughly flat year over year (H1 2025: $18.0M vs H1 2024: $18.09M), indicating some cost control while scaling R&D.
* Other income from investments and FX partially offsets interest expense; interest expense decreased (H1 2025: $0.135M vs H1 2024: $0.326M).

Income statement - negatives / risks
* Revenue fall and concentration: Q2 partner revenue down 53% YoY; revenue is uneven and concentrated with a few partners - raises business risk and forecasting difficulty.
* Large and growing losses: net loss widened to $(56.9)M for H1 2025 (vs $(46.7)M prior year) driven by higher R&D spend; operating loss and cash burn remain substantial.
* Cash runway dependent on financing: the company required equity raises in H1 2025 and additional offerings in July 2025 to bolster cash - ongoing dilution risk for shareholders.
* Accumulated deficit large: $566.5M- reflects multi‑year investment stage and the long lead times of biologics development.

Milestones & near‑term catalysts to watch
* ABS‑101 Phase 1 - interim readout expected in H2 2025 (reported by company).
* ABS‑201 - targeted IND or comparable filing in H1 2026 (company guidance).
* Partnering / licensing events - converting drug‑creation work into milestone/royalty bearing licenses is the primary path to recurring, higher‑margin revenue; timing is uncertain and milestone‑dependent.
* Cash/capital events - July 2025 follow‑on raises (~$60.6M net) materially improve liquidity, but continued investment needs and burn rate imply future financing may still be required.

Bottom line (straightforward)
* Absci (NASDAQ: ABSI) is aggressively funding R&D to validate its AI drug‑creation platform and advance internal candidates - that's positive for long‑term upside if programs succeed.
* Near term the picture is typical for a clinical‑stage biotech: partner revenue is small and lumpy, losses are large and rising, cash is finite and supplemented by equity raises (dilutive).
* Key investor risks: revenue concentration, continued cash burn, milestone timing uncertainty, and the binary nature of clinical readouts. Key potential rewards: successful clinical validation, licensing/deals that convert platform work into milestone/royalty streams.

If you want, I can prepare a one‑page investor brief (short slide‑style) summarizing runway estimates after the July 2025 raises, upcoming milestones and a simple sensitivity of cash runway to monthly burn rates.